NCT05484583View on ClinicalTrials.gov

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2027

Conditions
Lung CancerExtensive-stage Small-cell Lung CancerRadiotherapy
Interventions
DRUG

Durvalumab + carboplatin/cisplatin + etoposide

Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip

RADIATION

Consolidation radiotherapy

Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.

DRUG

Durvalumab

Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion

All Listed Sponsors
lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

NCT05484583 - Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | Biotech Hunter | Biotech Hunter